SARS-CoV-2 Spike Monoclonal Antibodies

Exonbio has developed SARS-CoV-2 Spike recombinant monoclonal antibodies for the global IVD and research communities in support of efforts to combat the pandemic.  By using Exonbio’s SPIN® technology platform, highly specific antibodies from plasma cells are generated against spike protein of SARS-CoV-2. These high affinity and sensitivity antibodies can be used for antigen detection of diagnostic kit development.

SARS-CoV-2 Spike S1 protein IgG mAbs

Clone IDIsotypeSpeciesEC50 (ng/ml)

Please reach out to us at for more information about our SARS-CoV-2 Spike S1 protein monoclonal antibodies.

Epitope Mapping

High-affinity monoclonal antibodies that fall in different epitope bins allow for antibody pairing for the development of ELISA kit. For detailed Spike monoclonal pairing & clone information contact us.

Validation Data

ELISA: Spike S1 protein IgG mAbs are high affinity, with EC50 range between 2.1-7.2 ng/ml.

Figure A: EC50 assay of anti-spike S1 rabbit monoclonal antibodies. Full-length recombinant spike protein (Catalog # 19CoV-S110) were coated on ELISA plate at 2 ug/ml.Detection antibody is HRP conjugated goat anti-rabbit IgG antibody at 1:10,000. Data was modeled and analyzed with GraphPad-Prism.

Neutralization Assay: The S1-targeting monoclonal antibodies blocks the interaction between receptor binding domain and ACE2 receptor and exhibits high levels of neutralization activity.

Figure B: Anti-spike antibodies (5 ug/ml ) were added to a FRET assay between RBD of spike protein and ACE2 receptor. Commercially available positive control antibody claimed IC50 at 1.5 ug/ml.